Novaliq GmbH: Novaliq submits New Drug Application seeking a

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Heidelberg , Baden Wüberg , Germany , United States , Netherlands , Holland , Americans , Christian Roesky , Mathias Hothum , Novaliq Gmb , Kostenloser Wertpapierhandel , Prnewswire Novaliq , Simone Angstmann Mehr , Clin Ophthalmol , Gmbh Co , Drug Administration , Novaliq Inc , Cornea Clinical Committee , Health Sciences , New Drug Application , Hopp Biotech , Dry Eye , Eye Products Market Report , Clinical Committee , Cataract Refract , Dry Eye Disease , Randomized Phase , Clinical Phase , Assess Efficacy , Waterfree Cyclosporine Formulation , Media Contact , Novaliq , Mbh , Ubmits , Drug , Application , Seeking , Approval , First , Wind , Disease , Treatment , Yclasol ,